vTv Therapeutics (VTVT)
(Delayed Data from NSDQ)
$19.00 USD
-2.50 (-11.63%)
Updated Jun 5, 2024 04:00 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
VTVT 19.00 -2.50(-11.63%)
Will VTVT be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for VTVT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VTVT
VTv Therapeutics (VTVT) Reports Q3 Loss, Lags Revenue Estimates
Exact Sciences (EXAS) Reports Q3 Loss, Tops Revenue Estimates
VTVT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Acadia Pharmaceuticals (ACAD) Reports Q3 Loss, Misses Revenue Estimates
Is Immunocore (IMCR) Stock Outpacing Its Medical Peers This Year?
Regeneron (REGN), Sanofi Get Priority Review for Dupixent sBLA
Other News for VTVT
Goldman Sachs raises obesity drug market estimate to $130B
CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING
Cantex Pharmaceuticals receives FDA Orphan Drug Designation for its pancreatic cancer treatment
CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF PANCREATIC CANCER
VTv Therapeutics: Q1 Earnings Snapshot